Cadence Pharmaceuticals Inc (CADX) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
12481 HIGH BLUFF DRIVE SAN DIEGO, CA 92130 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2013 | 12/31/2012 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments | 62,072 | |||
| Cash and cash equivalents | 58,327 | |||
| Short-term investments | 3,745 | |||
| Restricted cash and investments | 640 | |||
| Receivables | 6,152 | |||
| Inventory, net of allowances, customer advances and progress billings | 6,498 | |||
| Inventory | 6,498 | |||
| Prepaid expense | ✕ | |||
| Prepaid expense and other current assets | ✕ | 1,154 | ||
| Other current assets | ✕ | |||
| Total current assets: | 76,516 | |||
| Noncurrent Assets | ||||
| Property, plant and equipment | 1,967 | |||
| Intangible assets, net (including goodwill) | 12,090 | |||
| Intangible assets, net (excluding goodwill) | 12,090 | |||
| Restricted cash and investments | ||||
| Other noncurrent assets | ✕ | |||
| Prepaid expense and other noncurrent assets | ✕ | 7,106 | ||
| Total noncurrent assets: | 21,163 | |||
| TOTAL ASSETS: | 97,679 | |||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 18,765 | |||
| Accounts payable | 5,796 | |||
| Accrued liabilities | 12,969 | |||
| Debt | ||||
| Asset retirement obligation | 750 | |||
| Deferred revenue and credits | 2,234 | |||
| Other undisclosed current liabilities | (750) | |||
| Total current liabilities: | 20,999 | |||
| Noncurrent Liabilities | ||||
| Long-term debt and lease obligation | 28,818 | |||
| Long-term debt, excluding current maturities | 28,818 | |||
| Liabilities, other than long-term debt | 51 | |||
| Other liabilities | 51 | |||
| Total noncurrent liabilities: | 28,869 | |||
| Total liabilities: | 49,868 | |||
| Equity | ||||
| Equity, attributable to parent | 47,811 | |||
| Common stock | 9 | |||
| Additional paid in capital | 495,458 | |||
| Accumulated deficit | (447,656) | |||
| Total equity: | 47,811 | |||
| TOTAL LIABILITIES AND EQUITY: | 97,679 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|
| Revenues | 50,184 | ||
| Revenue, net | 50,302 | ||
| Cost of revenue (Cost of Goods and Services Sold) | (23,419) | ||
| Other undisclosed gross profit | 163 | ||
| Gross profit: | 26,928 | ||
| Operating expenses | (103,725) | ||
| Other operating income, net | |||
| Other undisclosed operating income | 123 | ||
| Operating loss: | (76,674) | ||
| Nonoperating income (expense) | (4,299) | ||
| Other nonoperating income | 27 | ||
| Interest and debt expense | (4,449) | ||
| Loss from continuing operations before equity method investments, income taxes: | (85,422) | ||
| Other undisclosed income from continuing operations before income taxes | 4,449 | ||
| Loss from continuing operations: | (80,973) | ||
| Loss before gain (loss) on sale of properties: | (80,973) | ||
| Net loss available to common stockholders, diluted: | (80,973) | ||
Comprehensive Income ($ in thousands)
| 12/31/2013 | 12/31/2012 | ||
|---|---|---|---|
| Net loss: | (80,973) | ||
| Other comprehensive loss | (2) | ||
| Comprehensive loss, net of tax, attributable to parent: | (80,975) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.